Integrated Filing — IndAS


General information about company

Scrip Code 543264
NSE Symbol NURECA
MSEI Symbol NOTLIDTED
ISIN INE0DSF01015
Name of company NURECA LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-Apr-2024
Date of end of financial year 31-Mar-2025
Date of board meeting when results were approved 05-May-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 28-Apr-2025
Description of presentation currency INR (in Actuals)
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment NOT APPLICABLE
Start date and time of board meeting 05-May-2025   16:30:00
End date and time of board meeting 05-May-2025   18:25:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 2022-04-01
Indicate Company website link for updated RPT policy of the Company https://www.nureca.com/wp-content/uploads/2021/07/Policy%20for%20consideration%20and%20approval%20of%20related%20party%20transactions%20effective%20from%20April%2001%2C%202022.pdf?_t=1646311307
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? Yes



Financial Results Ind-AS

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Income
Revenue from operations 317500000 1146400000
Other income 19980000 125400000
Total income 337480000 1271800000
2 Expenses
(a) Cost of materials consumed 0 0
(b) Purchases of stock-in-trade 308780000 864890000
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade -101860000 -68040000
(d) Employee benefit expense 39820000 143560000
(e) Finance costs 5940000 11150000
(f) Depreciation, depletion and amortisation expense 4750000 21530000
(f) Other Expenses
1 Other expenses 65070000 303310000
Total other expenses 65070000 303310000
Total expenses 322500000 1276400000
3 Total profit before exceptional items and tax 14980000 -4600000
4 Exceptional items 0 0
5 Total profit before tax 14980000 -4600000
6 Tax expense
7 Current tax -20850000 -11980000
8 Deferred tax 15110000 14060000
9 Total tax expenses -5740000 2080000
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0 0
11 Net Profit Loss for the period from continuing operations 20720000 -6680000
12 Profit (loss) from discontinued operations before tax 0 0
13 Tax expense of discontinued operations 0 0
14 Net profit (loss) from discontinued operation after tax 0 0
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0 0
16 Total profit (loss) for period 20720000 -6680000
17 Other comprehensive income net of taxes 2580000 2880000
18 Total Comprehensive Income for the period 23300000 -3800000
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 100000000 100000000
Face value of equity share capital 10 10
27 Details of debt securities
22 Reserves excluding revaluation reserve 0
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 2.07 -0.67
Diluted earnings (loss) per share from continuing operations 2.07 -0.67
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 2.07 -0.67
Diluted earnings (loss) per share from continuing and discontinued operations 2.07 -0.67
24 Debt equity ratio 0 0.0001
25 Debt service coverage ratio 0 0.0124
26 Interest service coverage ratio 0 0
27 Disclosure of notes on financial results



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2024
Date of end of reporting period 31-Mar-2025
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 36320000
Capital work-in-progress 0
Investment property 0
Goodwill 0
Other intangible assets 19650000
Intangible assets under development 0
Biological assets other than bearer plants 0
Investments accounted for using equity method 0
Non-current financial assets
Non-current investments 30560000
Trade receivables, non-current 0
Loans, non-current 0
Other non-current financial assets 41120000
Total non-current financial assets 71680000
Deferred tax assets (net) 33730000
Other non-current assets 56410000
Total non-current assets 217790000
2 Current assets
Inventories 355480000
Current financial asset
Current investments 10430000
Trade receivables, current 45250000
Cash and cash equivalents 31880000
Bank balance other than cash and cash equivalents 430120000
Loans, current 6180000
Other current financial assets 829520000
Total current financial assets 1353380000
Current tax assets (net) 0
Other current assets 134940000
Total current assets 1843800000
3 Non-current assets classified as held for sale 0
4 Regulatory deferral account debit balances and related deferred tax Assets 0
Total assets 2061590000
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 100000000
Other equity 1824790000
Total equity attributable to owners of parent 1924790000
Non controlling interest
Total equity 1924790000
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 10470000
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0
Total Trade payable 0
Other non-current financial liabilities 15430000
Total non-current financial liabilities 25900000
Provisions, non-current 6490000
Deferred tax liabilities (net) 0
Deferred government grants, Non-current 0
Other non-current liabilities 0
Total non-current liabilities 32390000
Current liabilities
Current financial liabilities
Borrowings, current 4760000
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 2380000
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 54180000
Total Trade payable 56560000
Other current financial liabilities 27600000
Total current financial liabilities 88920000
Other current liabilities 13270000
Provisions, current 2220000
Current tax liabilities (Net) 0
Deferred government grants, Current 0
Total current liabilities 104410000
3 Liabilities directly associated with assets in disposal group classified as held for sale 0
4 Regulatory deferral account credit balances and related deferred tax liability 0
Total liabilities 136800000
Total equity and liabilites 2061590000
Disclosure of notes on assets and liabilities



Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Jan-2025 01-Apr-2024
Date of end of reporting period 31-Mar-2025 31-Mar-2025
Whether accounts are audited or unaudited Audited Audited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Items that will not be reclassified to profit and loss 3450000 3850000
Total Amount of items that will not be reclassified to profit and loss 3450000 3850000
2 Income tax relating to items that will not be reclassified to profit or loss 870000 970000
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 0 0
5 Total Other comprehensive income 2580000 2880000



Cash flow statement, indirect

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 2024-04-01
B Date of end of reporting period 2025-03-31
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Standalone
Part I Blue color marked fields are non-mandatory.
Statement of cash flows
Cash flows from used in operating activities
Profit before tax -4600000
Adjustments for reconcile profit (loss)
Adjustments for finance costs 11150000
Adjustments for decrease (increase) in inventories -67900000
Adjustments for decrease (increase) in trade receivables, current -27150000
Adjustments for decrease (increase) in trade receivables, non-current 0
Adjustments for decrease (increase) in other current assets -26100000
Adjustments for decrease (increase) in other non-current assets 0
Adjustments for other financial assets, non-current 0
Adjustments for other financial assets, current 14700000
Adjustments for other bank balances 0
Adjustments for increase (decrease) in trade payables, current 8030000
Adjustments for increase (decrease) in trade payables, non-current 0
Adjustments for increase (decrease) in other current liabilities -9060000
Adjustments for increase (decrease) in other non-current liabilities 0
Adjustments for depreciation and amortisation expense 21530000
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0
Adjustments for provisions, current 1900000
Adjustments for provisions, non-current 0
Adjustments for other financial liabilities, current 17000000
Adjustments for other financial liabilities, non-current 0
Adjustments for unrealised foreign exchange losses gains -590000
Adjustments for dividend income 0
Adjustments for interest income 0
Adjustments for share-based payments 0
Adjustments for fair value losses (gains) 0
Adjustments for undistributed profits of associates 0
Other adjustments for which cash effects are investing or financing cash flow 0
Other adjustments to reconcile profit (loss) 0
Other adjustments for non-cash items -114060000
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0
Total adjustments for reconcile profit (loss) -170550000
Net cash flows from (used in) operations -175150000
Dividends received 0
Interest paid 0
Interest received 0
Income taxes paid (refund) 10330000
Other inflows (outflows) of cash 0
Net cash flows from (used in) operating activities -185480000
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0
Cash flows used in obtaining control of subsidiaries or other businesses -90000
Other cash receipts from sales of equity or debt instruments of other entities 0
Other cash payments to acquire equity or debt instruments of other entities 0
Other cash receipts from sales of interests in joint ventures 0
Other cash payments to acquire interests in joint ventures 0
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0
Proceeds from sales of property, plant and equipment 290000
Purchase of property, plant and equipment 39880000
Proceeds from sales of investment property 0
Purchase of investment property 0
Proceeds from sales of intangible assets 0
Purchase of intangible assets 0
Proceeds from sales of intangible assets under development 0
Purchase of intangible assets under development 0
Proceeds from sales of goodwill 0
Purchase of goodwill 0
Proceeds from biological assets other than bearer plants 0
Purchase of biological assets other than bearer plants 0
Proceeds from government grants 0
Proceeds from sales of other long-term assets 0
Purchase of other long-term assets 0
Cash advances and loans made to other parties 0
Cash receipts from repayment of advances and loans made to other parties 0
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0
Dividends received 0
Interest received 49140000
Income taxes paid (refund) 0
Other inflows (outflows) of cash 76000000
Net cash flows from (used in) investing activities 85640000
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0
Payments from changes in ownership interests in subsidiaries 0
Proceeds from issuing shares 0
Proceeds from issuing other equity instruments 0
Payments to acquire or redeem entity's shares 0
Payments of other equity instruments 0
Proceeds from exercise of stock options 0
Proceeds from issuing debentures notes bonds etc 0
Proceeds from borrowings 14410000
Repayments of borrowings 3250000
Payments of lease liabilities 10710000
Dividends paid 0
Interest paid 8330000
Income taxes paid (refund) 0
Other inflows (outflows) of cash 0
Net cash flows from (used in) financing activities -7880000
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes -107720000
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0
Net increase (decrease) in cash and cash equivalents -107720000
Cash and cash equivalents cash flow statement at beginning of period 139600000
Cash and cash equivalents cash flow statement at end of period 31880000







Details of Impact of Audit Qualification

Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 BSR & CO. LLP Yes 31-Jul-2025


Financial details

Sr. Particulars Audited Figures (as reported before adjusting for qualifications) Adjusted Figures (audited figures after adjusting for qualifications)
1 Turnover / Total income
2 Total Expenditure
3 Net Profit/(Loss)
4 Earnings Per Share
5 Total Assets
6 Total Liabilities
7 Net Worth




Signatories detail

Name of CEO / Managing director
Name of CFO
Name of audit committee chairman
Name of statutory auditor
Name of other signatory, if any, with designation
Place
Date



Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity /subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Nureca Limited Nureca Technologies Private Limited Wholly Owned Subsidiary Sale of goods or services 130000000 NA 7550000 0 0 Any other NA 0 0 Advance 0 NA Unsecured NA
2 Nureca Limited Mr. Saurabh Goyal Managing Director Remuneration 0 NA 10360000 940000 2470000 Any other NA 0 0 Advance 0 NA Unsecured NA Textual Information(1)
3 Nureca Limited Mrs. Payal Goyal Relatives of KMPs Any other transaction Salary to KMPs and their relatives 0 NA 6840000 710000 1210000 Any other NA 0 0 Advance 0 NA Unsecured NA Textual Information(2)
4 Nureca Limited Mr. Aryan Goyal Chief Executive officer Any other transaction Salary to KMPs and their relatives 0 NA 10660000 890000 2090000 Any other NA 0 0 Advance 0 NA Unsecured NA Textual Information(3)
5 Nureca Limited Mr. Naresh Gupta Chief Financial Officer Any other transaction Salary to KMPs and their relatives 0 NA 2010000 300000 340000 Any other NA 0 0 Advance 0 NA Unsecured NA Textual Information(4)
6 Nureca Limited Ms. Chetna Anand Company Secretary Any other transaction Salary to KMPs and their relatives 0 NA 480000 130000 0 Any other NA 0 0 Advance 0 NA Unsecured NA Textual Information(5)
7 Nureca Limited Ms. Nishu Kansal Company Secretary Any other transaction Salary to KMPs and their relatives 0 NA 260000 0 130000 Any other NA 0 0 Advance 0 NA Unsecured NA Textual Information(6)
8 Nureca Limited Mr. Rajinder Sharma Executive Director Any other transaction Salary to KMPs and their relatives 0 NA 150000 30000 30000 Any other NA 0 0 Advance 0 NA Unsecured NA Textual Information(7)
9 Nureca Limited Mr. Vijay Kumar Sharma Independent Director Any other transaction Sitting fee 0 NA 360000 0 0 Any other NA 0 0 Advance 0 NA Unsecured NA Textual Information(8)
10 Nureca Limited Mrs. Ruchita Agarwal Independent Director Any other transaction Sitting fee 0 NA 40000 0 0 Any other NA 0 0 Advance 0 NA Unsecured NA Textual Information(9)
11 Nureca Limited Ms. Charu Singh Independent Director Any other transaction Sitting fee 0 NA 20000 0 0 Any other NA 0 0 Advance 0 NA Unsecured NA Textual Information(10)
12 Nureca Limited Mr. Vikram Chaudhery Independent Director Any other transaction Sitting fee 0 NA 0 0 0 Any other NA 0 0 Advance 0 NA Unsecured NA Textual Information(11)
13 Nureca Limited Dr. Rupinder Tewari Independent Director Any other transaction Sitting fee 0 NA 20000 0 0 Any other NA 0 0 Advance 0 NA Unsecured NA Textual Information(12)
14 Nureca Limited Dr. Kuldip Kumar Bhasin Independent Director Any other transaction Sitting fee 0 NA 20000 0 0 Any other NA 0 0 Advance 0 NA Unsecured NA Textual Information(13)
15 Nureca Limited Nureca Healthcare Private Limited Wholly Owned Subsidiary Any other transaction Rent Income 0 NA 10000 20000 30000 Any other NA 0 0 Advance 0 NA Unsecured NA Textual Information(14)
16 Nureca Limited Nureca Technologies Private Limited Wholly Owned Subsidiary Any other transaction Rent Income 0 NA 450000 0 0 Any other NA 0 0 Advance 0 NA Unsecured NA Textual Information(15)
17 Nureca Limited Nureca Inc Wholly Owned Subsidiary Any other transaction Investment in equity shares 0 NA 0 460000 460000 Any other NA 0 0 Advance 0 NA Unsecured working capital requirement
18 Nureca Limited Nureca Healthcare Private Limited Wholly Owned Subsidiary Any other transaction Investment in equity shares 0 NA 0 100000 100000 Any other NA 0 0 Advance 0 NA Unsecured working capital requirement
19 Nureca Limited Nureca Technologies Private Limited Wholly Owned Subsidiary Any other transaction Investment in equity shares 0 NA 0 30000000 30000000 Any other NA 0 0 Advance 0 NA Unsecured working capital requirement
20 Nureca Limited Nureca Technologies Private Limited Wholly Owned Subsidiary Any other transaction Interest on borrowing given 100000000 NA 250000 0 0 Any other NA 0 0 Advance 0 NA Unsecured NA
21 Nureca Limited Nureca Healthcare Private Limited Wholly Owned Subsidiary Any other transaction Interest on borrowing given 100000000 NA 10000 10000 20000 Any other NA 0 0 Advance 0 NA Unsecured NA
22 Nureca Limited Nureca Technologies Private Limited Wholly Owned Subsidiary Purchase of goods or services 500000000 NA 123010000 160000 3460000 Any other NA 0 0 Advance 0 NA Unsecured NA
23 Nureca Limited Nureca Inc Wholly Owned Subsidiary Any other transaction Reimbursement of expense paid by the company 0 NA 60000 2260000 2320000 Any other NA 0 0 Advance 0 NA Unsecured NA Textual Information(16)
24 Nureca Limited Nureca Technologies Private Limited Wholly Owned Subsidiary Loan 100000000 NA 0 6160000 6160000 Loan 0 0 Loan 0.08 3 years Unsecured working capital requirement
25 Nureca Limited Nureca Healthcare Private Limited Wholly Owned Subsidiary Loan 300000 NA 0 200000 200000 Loan 0 0 Loan 0.08 3 years Unsecured working capital requirement
26 Nureca Limited Nureca Technologies Private Limited Wholly Owned Subsidiary Any other transaction Security Deposit received against property rented 110000 NA 0 110000 110000 Any other NA 0 0 Advance 0 NA Unsecured NA
27 Nureca Limited Nureca Technologies Private Limited Wholly Owned Subsidiary Any other transaction Reimbursement of expense paid by the company 0 NA 320000 0 0 Any other NA 0 0 Advance 0 NA Unsecured NA Textual Information(17)
Total value of transaction during the reporting period 162880000



Text Block

Textual Information(1) Audit Committee approval has been received on all perpetual transactions for the term of managerial remuneration / salary to KMPs / sitting fees/reimbursement of expenses/ Fees on Corporate Gurantee. Further approval from audit committee/board has been seen as per the provisions of the Companies Act, 2013
Textual Information(2) Audit Committee approval has been received on all perpetual transactions for the term of managerial remuneration / salary to KMPs / sitting fees/reimbursement of expenses/ Fees on Corporate Gurantee. Further approval from audit committee/board has been seen as per the provisions of the Companies Act, 2013
Textual Information(3) Audit Committee approval has been received on all perpetual transactions for the term of managerial remuneration / salary to KMPs / sitting fees/reimbursement of expenses/ Fees on Corporate Gurantee. Further approval from audit committee/board has been seen as per the provisions of the Companies Act, 2013
Textual Information(4) Audit Committee approval has been received on all perpetual transactions for the term of managerial remuneration / salary to KMPs / sitting fees/reimbursement of expenses/ Fees on Corporate Gurantee. Further approval from audit committee/board has been seen as per the provisions of the Companies Act, 2013
Textual Information(5) Audit Committee approval has been received on all perpetual transactions for the term of managerial remuneration / salary to KMPs / sitting fees/reimbursement of expenses/ Fees on Corporate Gurantee. Further approval from audit committee/board has been seen as per the provisions of the Companies Act, 2013
Textual Information(6) Audit Committee approval has been received on all perpetual transactions for the term of managerial remuneration / salary to KMPs / sitting fees/reimbursement of expenses/ Fees on Corporate Gurantee. Further approval from audit committee/board has been seen as per the provisions of the Companies Act, 2013
Textual Information(7) Audit Committee approval has been received on all perpetual transactions for the term of managerial remuneration / salary to KMPs / sitting fees/reimbursement of expenses/ Fees on Corporate Gurantee. Further approval from audit committee/board has been seen as per the provisions of the Companies Act, 2013
Textual Information(8) Audit Committee approval has been received on all perpetual transactions for the term of managerial remuneration / salary to KMPs / sitting fees/reimbursement of expenses/ Fees on Corporate Gurantee. Further approval from audit committee/board has been seen as per the provisions of the Companies Act, 2013
Textual Information(9) Audit Committee approval has been received on all perpetual transactions for the term of managerial remuneration / salary to KMPs / sitting fees/reimbursement of expenses/ Fees on Corporate Gurantee. Further approval from audit committee/board has been seen as per the provisions of the Companies Act, 2013
Textual Information(10) Audit Committee approval has been received on all perpetual transactions for the term of managerial remuneration / salary to KMPs / sitting fees/reimbursement of expenses/ Fees on Corporate Gurantee. Further approval from audit committee/board has been seen as per the provisions of the Companies Act, 2013
Textual Information(11) Audit Committee approval has been received on all perpetual transactions for the term of managerial remuneration / salary to KMPs / sitting fees/reimbursement of expenses/ Fees on Corporate Gurantee. Further approval from audit committee/board has been seen as per the provisions of the Companies Act, 2013
Textual Information(12) Audit Committee approval has been received on all perpetual transactions for the term of managerial remuneration / salary to KMPs / sitting fees/reimbursement of expenses/ Fees on Corporate Gurantee. Further approval from audit committee/board has been seen as per the provisions of the Companies Act, 2013
Textual Information(13) Audit Committee approval has been received on all perpetual transactions for the term of managerial remuneration / salary to KMPs / sitting fees/reimbursement of expenses/ Fees on Corporate Gurantee. Further approval from audit committee/board has been seen as per the provisions of the Companies Act, 2013
Textual Information(14) Audit Committee approval has been received on all perpetual transactions for the term of managerial remuneration / salary to KMPs / sitting fees/reimbursement of expenses/ Fees on Corporate Gurantee. Further approval from audit committee/board has been seen as per the provisions of the Companies Act, 2013
Textual Information(15) Audit Committee approval has been received on all perpetual transactions for the term of managerial remuneration / salary to KMPs / sitting fees/reimbursement of expenses/ Fees on Corporate Gurantee. Further approval from audit committee/board has been seen as per the provisions of the Companies Act, 2013
Textual Information(16) Audit Committee approval has been received on all perpetual transactions for the term of managerial remuneration / salary to KMPs / sitting fees/reimbursement of expenses/ Fees on Corporate Gurantee. Further approval from audit committee/board has been seen as per the provisions of the Companies Act, 2013.
Textual Information(17) Audit Committee approval has been received on all perpetual transactions for the term of managerial remuneration / salary to KMPs / sitting fees/reimbursement of expenses/ Fees on Corporate Gurantee. Further approval from audit committee/board has been seen as per the provisions of the Companies Act, 2013.


Format for Disclosing Outstanding Default on Loans and Debt Securities

Sr. No. Particulars Amount Remarks
1. Loans / revolving facilities like cash credit from banks / financial institutions
A Total amount outstanding as on date 15230000
B Of the total amount outstanding, amount of default as on date 0
2. Unlisted debt securities i.e. NCDs and NCRPS
A Total amount outstanding as on date 0
B Of the total amount outstanding, amount of default as on date 0
3. Total financial indebtedness of the listed entity including short-term and long-term debt 15230000